The complement inhibitors in COVID-19: Future expectations

Korotchaeva Y.¹ , Kozlovskaya N. ² , Bobrova L.¹ , Kamyshova E.¹ , Demyanova K. ² , Moiseev S.¹

European Review for Medical and Pharmacological Sciences

Verduci Editore

12

Английский

6480-6481

Опубликовано

Внешняя ссылка

10.26355/EURREV_202006_21628

24

2020

• ¹ Sechenov First Moscow State Medical University, Moscow, Russian Federation
• ² Peoples' Friendship University of Russia, Moscow, Russian Federation

complement component C5a; complement inhibitor; eculizumab; complement inhibitor; eculizumab; monoclonal antibody; adult respiratory distress syndrome; coronavirus disease 2019; cytokine storm; disease predisposition; disease severity; drug efficacy; drug inhibition; heredity; human; infection risk; Letter; lung biopsy; lung injury; multiple organ failure; mutation; nonhuman; prediction; protein blood level; Severe acute respiratory syndrome coronavirus 2; thrombotic thrombocytopenic purpura; treatment duration; Betacoronavirus; Coronavirus infection; motivation; pandemic; virus pneumonia; Antibodies, Monoclonal, Humanized; Betacoronavirus; Complement Inactivating Agents; Coronavirus Infections; Humans; Motivation; Pandemics; Pneumonia, Viral